Ironwood Pharmaceuticals Q2 2024 Adj. EPS $0.00 Misses $0.15 Estimate, Sales $94.396M Miss $106.996M Estimate
Portfolio Pulse from Benzinga Newsdesk
Ironwood Pharmaceuticals reported Q2 2024 adjusted EPS of $0.00, missing the estimate of $0.15. Sales were $94.396 million, falling short of the $106.996 million estimate.
August 08, 2024 | 11:03 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ironwood Pharmaceuticals reported disappointing Q2 2024 results with adjusted EPS of $0.00 missing the $0.15 estimate and sales of $94.396 million missing the $106.996 million estimate.
The significant miss on both EPS and sales estimates is likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100